Pricing Log in Create free account
Friday 6 November 2026 Export GSK’s income statement to Excel — free account

GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.

Revenue
+3.75%
EPS
−14.7%
Free cash flow
+62.4%
Total debt
+33.2%

Quarter to September 2026, against a year earlier

50.19 0.22 −0.44%
Market cap
$101.0B
P/E
16.7×
Fwd P/E
14.6×
Dividend yield
3.60%
F-score
9/9
Altman Z
2.12
Beneish M
−2.46
Dividend safety
54/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

GSK PLC Sponsored ADR (GSK) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, GSK PLC Sponsored ADR (GSK) trades at a EV/EBITDA of 10.6×. Over the past ten years it has ranged from 4.9× (February 2016) to 22.9× (August 2015); the current reading is higher than 53% of that period. That is below the Drug Manufacturers General industry median of 14.8× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 8.7× (14.22%)
FY2024 10.2× 24.74%
FY2023 8.2× (0.43%)
FY2022 8.2× (32.54%)
FY2021 12.2× 33.98%
FY2020 9.1× (27.51%)
FY2019 12.5× (0.43%)
FY2018 12.6× (9.12%)
FY2017 13.8× (27.48%)
FY2016 19.1× 271.03%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 10.2× 4.05%
Jun 2026 9.8× (0.54%)
Mar 2026 9.8× 12.72%
Dec 2025 8.7× 15.46%
43 more quarters

Against its own ten years

Low 4.9× High 22.9×
Ten-year median 10.3×
Current reading's percentile 53

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.3×
GSK GSK PLC Sponsored ADR 10.6×
PFE Pfizer Inc. compare 10.9×
BMY Bristol Myers Squibb Company compare 11.3×
SNY Sanofi compare 11.4×
AZN AstraZeneca PLC compare 14.8×
AMGN Amgen Inc. compare 17.6×
BIIB Biogen Inc. compare 18.4×
GILD Gilead Sciences, Inc. compare 505×
Drug Manufacturers General industry median 14.8×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on GSK